Home / Expertise / Life Sciences & Healthcare
Lab

Life Sciences & Healthcare

Czech Republic

Our Prague team regularly advises pharmaceutical companies and medical device manufacturers on a range of commercial and regulatory issues.

We work with and have established long-term relationships with the top 100 lifesciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our lifesciences teams in Central and Eastern Europe advise leading global business groups in the sector on transactions, commercial agreements, compliance, investigations and litigation, very often across multiple jurisdictions in the region and beyond. We can help you to navigate the regulatory landscape and to ensure compliance with both local laws and global policies.

With over 150 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.

With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice.

Read more Read less

Feed

Show only
30 October 2019
CMS ad­vises Ad­vent In­ter­na­tion­al and Zentiva on ac­quis­i­tion...
06 Apr 20
Czech drug au­thor­ity re­com­mend­a­tions on clin­ic­al tri­als
The Czech State In­sti­tute for Drug Con­trol (SUKL) re­cently pub­lished its opin­ion on on­go­ing clin­ic­al tri­als and clin­ic­al tri­als that have not yet star­ted in light of the COV­ID-19 situ­ation. With the ex­cep­tion...
CMS Ex­pert Guide to a Leg­al Roadmap to Can­nabis
02 Apr 20
Czech pro­cure­ment rules waived for COV­ID-19 emer­gency med­ic­al sup­plies
In light of the state of emer­gency in the Czech Re­pub­lic de­clared on 12 March 2020, the Of­fice for the Pro­tec­tion of Com­pet­i­tion of the Czech Re­pub­lic is­sued a state­ment that pro­cure­ment rules can be...
CMS Ex­pert Guide to Ad­vert­ising of Medi­cines and Med­ic­al...
27 Mar 20
Man­aging clin­ic­al tri­als un­der COV­ID-19: New EU guid­ance is­sued for...
The COV­ID-19 pan­dem­ic has had a dra­mat­ic im­pact on European health sys­tems, whose pri­or­ity first and fore­most is the treat­ment of pa­tients suf­fer­ing from this dis­ease both in the in-pa­tient and out-pa­tient...
26 Mar 20
European Com­mis­sion pro­poses delay­ing the May 2020 ap­plic­a­tion of...
The European Com­mis­sion has con­firmed it is work­ing on a pro­pos­al to delay for one year the date of ap­plic­a­tion of the new EU Med­ic­al Devices Reg­u­la­tion 2017/745/EU (the “MDR”) in light of the Cov­id-19...
17 Mar 20
While doc­tors fight COV­ID-19 au­thor­it­ies battle fraud, price hikes...
In every coun­try hit by COV­ID-19, the dis­ease linked to the Coronavir­us, com­pet­i­tion and con­sumer pro­tec­tion au­thor­it­ies have been con­fron­ted with the vir­us's im­plic­a­tions. Gov­ern­ments, au­thor­it­ies and...
10 Mar 20
EU Com­mis­sion's White Pa­per on Ar­ti­fi­cial In­tel­li­gence stresses ex­cel­lence...
Ar­ti­fi­cial in­tel­li­gence (AI) has now reached al­most all areas of life: mo­bil­ity, trade and health, to name but a few. As a res­ult, the EU Com­mis­sion has sum­mar­ised its vis­ion for the fu­ture of AI and...
06 Mar 20
MDR - Agree­ments with third party con­tract man­u­fac­tur­ers
The EU Med­ic­al Device Reg­u­la­tion, which comes in­to force on 26 May 2020, will lead not only to big changes in how med­ic­al devices are reg­u­lated, but also to more thought be­ing giv­en to agree­ments between...
28 Feb 20
Pat­ent­ing Ar­ti­fi­cial In­tel­li­gence and quantum tech­no­lo­gies
IP and Life Sci­ence ana­lys­is: Caitlin Heard, IP Lit­ig­a­tion Part­ner, and Rachel Free, Pat­ent At­tor­ney and Part­ner, at CMS Camer­on McK­enna, dis­cuss the ap­plic­ab­il­ity of Ar­ti­fi­cial In­tel­li­gence (AI) and...
26 Feb 20
Can­nabis mark ruled con­trary to pub­lic policy
Back­ground On 19 Decem­ber 2016, Ms Santa Conte (“Ms Conte”) made an ap­plic­a­tion to re­gister an EU trade mark for the fol­low­ing fig­ur­at­ive sign in re­la­tion to vari­ous food and drink products and ser­vices...